Last Updated: September 24, 2026

Details for Patent: 12,358,862


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,358,862 protect, and when does it expire?

Patent 12,358,862 protects CUVRIOR and is included in one NDA.

This patent has forty-four patent family members in twenty-seven countries.

Summary for Patent: 12,358,862
Title:Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
Abstract:The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
Inventor(s):Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
Assignee: Gmp-Orphan SA , Orphalan SA
Application Number:US18/948,050
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 12,358,862
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 12,358,862

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Orphalan CUVRIOR trientine tetrahydrochloride TABLET;ORAL 215760-001 Apr 28, 2022 RX Yes Yes 12,358,862 ⤷  Start Trial Y Y A METHOD FOR THE TREATMENT OF ADULT PATIENTS WITH STABLE WILSON'S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.